MTOR and renal cell carcinoma: Recently, research on the molecular mechanisms underlying the initiation and progression of RCC has primarily focused on signaling pathways such as von Hippel–Lindau (VHL)/hypoxia‐inducible factor (HIF), phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), p53, cyclic adenosine monophosphate (cAMP), and transforming growth factor (TGF)‐β.2